KeyCorp Increases Danaher (NYSE:DHR) Price Target to $310.00

Danaher (NYSE:DHR) had its target price raised by stock analysts at KeyCorp from $290.00 to $310.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the conglomerate’s stock. KeyCorp’s price objective suggests a potential upside of 25.06% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. Robert W. Baird reduced their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday. TD Cowen raised their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. The Goldman Sachs Group increased their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Stifel Nicolaus boosted their price target on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Finally, Evercore ISI increased their price objective on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $287.28.

Danaher Stock Performance

Shares of DHR opened at $247.88 on Wednesday. The firm has a market cap of $183.60 billion, a P/E ratio of 42.01, a PEG ratio of 4.49 and a beta of 0.83. Danaher has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm’s 50 day moving average price is $270.43 and its two-hundred day moving average price is $260.43.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the firm earned $2.02 EPS. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, analysts forecast that Danaher will post 7.59 EPS for the current fiscal year.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at $8,229,254.88. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,059 shares of company stock valued at $8,400,897. Insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DHR. Tsfg LLC lifted its holdings in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the second quarter valued at approximately $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher in the 2nd quarter valued at $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher in the 1st quarter valued at $30,000. Finally, MFA Wealth Advisors LLC acquired a new position in shares of Danaher during the 2nd quarter worth $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.